Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 2/20 | 0.53 |
| ▸ | CHRNA4 known ✓ | P43681 | 2/20 | 0.53 |
| ▸ | NAMPT | P43490 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3015444 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4NAMPTCYP1A2CNR2 | |
| SCHEMBL7941626 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4NAMPTCYP1A2CNR2 | |
| SCHEMBL3012153 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4NAMPTCYP1A2CNR2 | |
| SCHEMBL7941619 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4NAMPTCYP1A2CNR2 | |
| SCHEMBL3015439 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4NAMPTCYP1A2CNR2 | |
| SCHEMBL3022216 | 0.91 | ROCK2 (0.41) | CHRNB2CHRNA4NAMPTCYP1A2CYP2C9 | |
| SCHEMBL3022211 | 0.91 | ROCK2 (0.41) | CHRNB2CHRNA4NAMPTCYP1A2CYP2C9 | |
| SCHEMBL3010633 | 0.84 | CHRNB2 (0.71) | CHRNB2CHRNA4AKT1GCKCHRNB4 | |
| SCHEMBL3010639 | 0.84 | CHRNB2 (0.71) | CHRNB2CHRNA4AKT1GCKCHRNB4 | |
| SCHEMBL3010587 | 0.84 | CHRNB2 (0.71) | CHRNB2CHRNA4AKT1GCKCHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288420-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2253616-A1 | Process for the preparation of compounds capable of activating cholinergic receptors | Targacept, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7790757-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100222395-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100204481-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100160390-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20080214628-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM SCOTT | 2008-09-04 | — | — | US | disclosed |
| US-20080139809-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM SCOTT | 2008-06-12 | — | — | US | disclosed |
| US-7307092-B2 | Compounds Capable of Activating Cholinergic Receptors | TARGACEPT, INC. (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1556352-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050148611-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM S (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050131034-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM S (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1086082-B9 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | TARGACEPT INC (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040214835-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM SCOTT (US) | 2004-10-28 | — | — | US | disclosed |
| EP-1086082-B1 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | TARGACEPT INC (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2004031151-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | TARGACEPT, INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. | 2002-05-02 | — | — | US | disclosed |
| US-6232316-B1 | SUCH AS PARKINSON'S DISEASE, TOURETTE'S SYNDROME, SCHIZOPHRENIA, AND SENILE DEMENTIA OF ALZHEIMERS DISEASE | TARGACEPT, INC. | 2001-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885NAMPT 1805/4885 |
| US-20100222395-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885NAMPT 1805/4885 |
| US-20050131034-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885NAMPT 1775/4885 |
| US-20050148611-A1 | Compounds capable of activating cholinergic receptors | CHRM3, CHRM5, CHRM4 | CHRNB2 14/4885CHRNA4 9/4885NAMPT 765/4885 |
| US-20100204481-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885NAMPT 1805/4885 |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | SLC6A2, CHRNA6, CHRNA10 | CHRNB2 9/4885CHRNA4 7/4885NAMPT 93/4885 |
| US-20080139809-A1 | Compounds Capable of Activating Cholinergic Receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885NAMPT 1805/4885 |
| US-20080214628-A1 | Compounds Capable of Activating Cholinergic Receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885NAMPT 1805/4885 |
| US-20040214835-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885NAMPT 1805/4885 |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRM3, CHRM5, CHRM4 | CHRNB2 14/4885CHRNA4 9/4885NAMPT 765/4885 |
| US-20100160390-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885NAMPT 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.